Qin L, Dong Z, Huang C, Liu H, Beebe J, Subramaniyan B, Hao Y, Liu Y, He Z, Liu JY, Zhang JT. Reversible promoter demethylation of PDGFD confers gemcitabine resistance through STAT3 activation and RRM1 upregulation. Cancer Lett. 2023 Jul 28;567:216266. doi: 10.1016/j.canlet.2023.216266. Epub 2023 Jun 14. PubMed PMID: 37321532.

 

Gurung D, Danielson JA, Tasnim A, Zhang JT, Zou Y, Liu JY. Proline Isomerization: From the Chemistry and Biology to Therapeutic Opportunities. Biology (Basel). 2023 Jul 14;12(7). doi: 10.3390/biology12071008. Review. PubMed PMID: 37508437; PubMed Central PMCID: PMC10376262.

​

Ma S, Liu JY, Zhang JT. eIF3d: A driver of noncanonical cap-dependent translation of specific mRNAs and a trigger of biological/pathological processes. J Biol Chem. 2023 May;299(5):104658. doi: 10.1016/j.jbc.2023.104658. Epub 2023 Mar 29. Review. PubMed PMID: 36997088; PubMed Central PMCID: PMC10165153.

​

Stefanski CD, Arnason A, Maloney S, Kotsen J, Powers E, Zhang JT, Prosperi JR. APC Loss Prevents Doxorubicin-Induced Cell Death by Increasing Drug Efflux and a Chemoresistant Cell Population in Breast Cancer. Int J Mol Sci. 2023 Apr 21;24(8). doi: 10.3390/ijms24087621. PubMed PMID: 37108784; PubMed Central PMCID: PMC10145529.

Ballinger TJ, Djuric Z, Sardesai S, Hovey KM, Andrews CA, Brasky TM, Zhang JT, Rohan TE, Saquib N, Shadyab AH, Simon M, Wactawski-Wende J, Wallace R, Kato I. Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women's Health Initiative. Nutr Cancer. 2023;75(1):265-275. doi: 10.1080/01635581.2022.2108467. Epub 2022 Aug 13. PubMed PMID: 35968582; PubMed Central PMCID: PMC9772040.

 

Beebe J, Josephraj S, Wang CJ, Danielson J, Cui Q, Huang C, Barlow L, Zhang RH, Zhang T, Nakshatri H, Dong Z, Li X, Liu JY, Zhang JT. Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase. J Med Chem. 2022 Oct 27;65(20):13681-13691. doi: 10.1021/acs.jmedchem.2c00642. Epub 2022 Oct 18. PubMed PMID: 36257066.

​

Ballinger TJ, Djuric Z, Sardesai S, Hovey KM, Andrews CA, Brasky TM, Zhang JT, Rohan TE, Saquib N, Shadyab AH, Simon M, Wactawski-Wende J, Wallace R, Kato I. Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women's Health Initiative. Nutr Cancer. 2022 Aug 13;:1-11. doi: 10.1080/01635581.2022.2108467. [Epub ahead of print] PubMed PMID: 35968582.

​

Peery R, Cui Q, Kyei-Baffour K, Josephraj S, Huang C, Dong Z, Dai M, Zhang JT, Liu JY. A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells. Bioorg Med Chem. 2022 Jul 1;65:116761. doi: 10.1016/j.bmc.2022.116761. Epub 2022 Apr 28. PubMed PMID: 35504208; PubMed Central PMCID: PMC9148172.

​

Ma S, Dong Z, Huang Y, Liu JY, Zhang JT. Translation initiation factor eIF3a regulates glucose metabolism and cell proliferation via promoting small GTPase Rheb synthesis and AMPK activation. J Biol Chem. 2022 Jul;298(7):102044. doi: 10.1016/j.jbc.2022.102044. Epub 2022 May 18. PubMed PMID: 35595099; PubMed Central PMCID: PMC9207673.

​

Peng K, Luo T, Li J, Huang J, Dong Z, Liu J, Pi C, Zou Z, Gu Q, Liu O, Zhang JT, Luo ZY. Ginsenoside Rh2 inhibits breast cancer cell growth viaERβ-TNFα pathway. Acta Biochim Biophys Sin (Shanghai). 2022 Apr 25;. doi: 10.3724/abbs.2022039. [Epub ahead of print] PubMed PMID: 35593465.

​

Ma S, Dong Z, Huang Y, Liu JY, Zhang JT. eIF3a regulation of mTOR signaling and translational control via HuR in cellular response to DNA damage. Oncogene. 2022 Apr;41(17):2431-2443. doi: 10.1038/s41388-022-02262-5. Epub 2022 Mar 12. PubMed PMID: 35279705; PubMed Central PMCID: PMC9035104.

​

Sardesai SD, Thomas A, Gallagher C, Lynce F, Ottaviano YL, Ballinger TJ, Schneider BP, Storniolo AM, Bauchle A, Althouse SK, Perkins SM, Masters AR, Stratford RE Jr, Dong Z, Liu JY, Zhang JT, Miller KD. Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC. Clin Cancer Res. 2021 Nov 1;27(21):5810-5817. doi: 10.1158/1078-0432.CCR-21-0493. Epub 2021 Aug 16. PubMed PMID: 34400413.

​

Chen J, Liu JY, Dong ZZ, Zou T, Wang Z, Shen Y, Zhuo W, Li XP, Xiao D, Liu HT, Chen X, Zhou HH, Liu ZQ, Zhang JT, Yin JY. The effect of eIF3a on anthracycline-based chemotherapy resistance by regulating DSB DNA repair. Biochem Pharmacol. 2021 Aug;190:114616. doi: 10.1016/j.bcp.2021.114616. Epub 2021 May 20. PubMed PMID: 34022189.

​

Wang CJ, Li D, Danielson JA, Zhang EH, Dong Z, Miller KD, Li L, Zhang JT, Liu JY. Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase. Cancer Lett. 2021 Jul 1;509:1-12. doi: 10.1016/j.canlet.2021.03.026. Epub 2021 Apr 1. PubMed PMID: 33813001; PubMed Central PMCID: PMC8167934.

​

Ma S, Dong Z, Cui Q, Liu JY, Zhang JT. eIF3i regulation of protein synthesis, cell proliferation, cell cycle progression, and tumorigenesis. Cancer Lett. 2021 Mar 1;500:11-20. doi: 10.1016/j.canlet.2020.12.009. Epub 2020 Dec 8. PubMed PMID: 33301799.

​

Liu SH, Yu J, Creeden JF, Sutton JM, Markowiak S, Sanchez R, Nemunaitis J, Kalinoski A, Zhang JT, Damoiseaux R, Erhardt P, Brunicardi FC. Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma. Cancer Lett. 2020 Oct 28;491:97-107. doi: 10.1016/j.canlet.2020.08.002. Epub 2020 Aug 21. PubMed PMID: 32829010.

​

Tumia R, Wang CJ, Dong T, Ma S, Beebe J, Chen J, Dong Z, Liu JY, Zhang JT. eIF3a Regulation of NHEJ Repair Protein Synthesis and Cellular Response to Ionizing Radiation. Front Cell Dev Biol. 2020;8:753. doi: 10.3389/fcell.2020.00753. eCollection 2020. PubMed PMID: 32974334; PubMed Central PMCID: PMC7466773.

​

Chen J, Zhang F, Ren X, Wang Y, Huang W, Zhang J, Cui Y. Targeting fatty acid synthase sensitizes human nasopharyngeal carcinoma cells to radiation via downregulating frizzled class receptor 10. Cancer Biol Med. 2020 Aug 15;17(3):740-752. doi: 10.20892/j.issn.2095-3941.2020.0219. PubMed PMID: 32944403; PubMed Central PMCID: PMC7476091.

​

Peery R, Kyei-Baffour K, Dong Z, Liu J, de Andrade Horn P, Dai M, Liu JY, Zhang JT. Synthesis and Identification of a Novel Lead Targeting Survivin Dimerization for Proteasome-Dependent Degradation. J Med Chem. 2020 Jun 9;. doi: 10.1021/acs.jmedchem. 0c00475. [Epub ahead of print] PubMed PMID: 32421328.

​

Dong Z, Liu J, Zhang JT. Translational regulation of Chk1 expression by eIF3a via interaction with the RNA-binding protein HuR. Biochem J. 2020 May 29;477(10):1939-1950. doi: 10.1042/BCJ20200025. PubMed PMID: 32391557.

​

Zhang W, Yang Y, Dong Z, Shi Z, Zhang JT. Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs. J Biol Chem. 2019 Dec 27;294(52):20222-20232. doi: 10.1074/jbc.RA119.008347. Epub 2019 Nov 12. PubMed PMID: 31719146; PubMed Central PMCID: PMC6937587.

​

Beebe J, Zhang JT. CC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance. J Pharmacol Exp Ther. 2019 Nov;371(2):320-326. doi: 10.1124/jpet.119.258392. Epub 2019 Aug 27. PubMed PMID: 31455631.

​

Beebe JD, Liu JY, Zhang JT. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?. Pharmacol Ther. 2018 Nov;191:74-91. doi: 10.1016/j.pharmthera.2018.06.006. Epub 2018 Jun 20. Review. PubMed PMID: 29933035.

​

Huang W, Liu Y, Wang J, Yuan X, Jin HW, Zhang LR, Zhang JT, Liu ZM, Cui JR. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis. Eur J Med Chem. 2018 Sep 5;157:887-897. doi: 10.1016/j.ejmech.2018.08.037. Epub 2018 Aug 14. PubMed PMID: 30145375.

​

Li X, Ma H, Li L, Chen Y, Sun X, Dong Z, Liu JY, Zhu W, Zhang JT. Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth. Oncogene. 2018 May;37(18):2469-2480. doi: 10.1038/s41388-017-0076-0. Epub 2018 Feb 19. PubMed PMID: 29456240; PubMed Central PMCID: PMC5934316.

​

Li J, Qu X, Tian J, Zhang JT, Cheng JX. Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation. PLoS One. 2018;13(2):e0193318. doi: 10.1371/journal.pone.0193318. eCollection 2018. PubMed PMID: 29489864; PubMed Central PMCID: PMC5831104.

​

Yin JY, Zhang JT, Zhang W, Zhou HH, Liu ZQ. eIF3a: A new anticancer drug target in the eIF family. Cancer Lett. 2018 Jan 1;412:81-87. doi: 10.1016/j.canlet.2017.09.055. Epub 2017 Oct 12. Review. PubMed PMID: 29031564.

​

Ozcelikkale A, Shin K, Noe-Kim V, Elzey BD, Dong Z, Zhang JT, Kim K, Kwon IC, Park K, Han B. Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model. J Control Release. 2017 Nov 28;266:129-139. doi: 10.1016/j.jconrel.2017.09.024. Epub 2017 Sep 20. PubMed PMID: 28939108; PubMed Central PMCID: PMC5723544.

​

VanKlompenberg MK, Leyden E, Arnason AH, Zhang JT, Stefanski CD, Prosperi JR. APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation. Oncotarget. 2017 Nov 28;8(61):102868-102879. doi: 10.18632/oncotarget.22263. eCollection 2017 Nov 28. PubMed PMID: 29262529; PubMed Central PMCID: PMC5732695.

​

Peery RC, Liu JY, Zhang JT. Targeting survivin for therapeutic discovery: past, present, and future promises. Drug Discov Today. 2017 Oct;22(10):1466-1477. doi: 10.1016/j.drudis.2017.05.009. Epub 2017 May 31. Review. PubMed PMID: 28577912.

​

Chen Y, Li Z, Dong Z, Beebe J, Yang K, Fu L, Zhang JT. 14-3-3σ Contributes to Radioresistance By Regulating DNA Repair and Cell Cycle via PARP1 and CHK2. Mol Cancer Res. 2017 Apr;15(4):418-428. doi: 10.1158/1541-7786.MCR-16-0366. Epub 2017 Jan 13. PubMed PMID: 28087741; PubMed Central PMCID: PMC5380477.

​

Yin JY, Dong Z, Zhang JT. eIF3 Regulation of Protein Synthesis, Tumorigenesis, and Therapeutic Response. Methods Mol Biol. 2017;1507:113-127. doi: 10.1007/978-1-4939-6518-2_9. PubMed PMID: 27832536.

​

Wu X, Dong Z, Wang CJ, Barlow LJ, Fako V, Serrano MA, Zou Y, Liu JY, Zhang JT. FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1. Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E6965-E6973. doi: 10.1073/pnas.1609934113. Epub 2016 Oct 24. PubMed PMID: 27791122; PubMed Central PMCID: PMC5111708.

​

Zhang JT, Liu JY. Drugging the "undruggable" DNA-binding domain of STAT3. Oncotarget. 2016 Oct 11;7(41):66324-66325. doi: 10.18632/oncotarget.12181. PubMed PMID: 27661130; PubMed Central PMCID: PMC5341805.

​

Qin L, Dong Z, Zhang JT. 14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression. Oncotarget. 2016 Apr 5;7(14):17726-36. doi: 10.18632/oncotarget.7394. PubMed PMID: 26894857; PubMed Central PMCID: PMC4951245.

​

Huang W, Dong Z, Chen Y, Wang F, Wang CJ, Peng H, He Y, Hangoc G, Pollok K, Sandusky G, Fu XY, Broxmeyer HE, Zhang ZY, Liu JY, Zhang JT. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene. 2016 Feb 11;35(6):783-92. doi: 10.1038/onc.2015.215. Epub 2015 Jun 15. PubMed PMID: 26073084.

​

Qi J, Dong Z, Liu J, Peery RC, Zhang S, Liu JY, Zhang JT. Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors. Cancer Res. 2016 Jan 15;76(2):453-62. doi: 10.1158/0008-5472.CAN-15-1874. Epub 2016 Jan 7. PubMed PMID: 26744521.

​

Fako VE, Wu X, Pflug B, Liu JY, Zhang JT. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase. J Med Chem. 2015 Jan 22;58(2):778-84. doi: 10.1021/jm501543u. Epub 2014 Dec 29. PubMed PMID: 25513712; PubMed Central PMCID: PMC4306520.

​

Qin L, Dong Z, Zhang JT. Reversible epigenetic regulation of 14-3-3σ expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1. Mol Pharmacol. 2014 Nov;86(5):561-9. doi: 10.1124/mol.114.092544. Epub 2014 Sep 4. PubMed PMID: 25189999; PubMed Central PMCID: PMC4201139.

​

Fako VE, Zhang JT, Liu JY. Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase. ACS Catal. 2014 Oct 3;4(10):3444-3453. doi: 10.1021/cs500956m. Epub 2014 Aug 21. PubMed PMID: 25309810; PubMed Central PMCID: PMC4188697.

​

Qi J, Dong Z, Liu J, Zhang JT. EIF3i promotes colon oncogenesis by regulating COX-2 protein synthesis and β-catenin activation. Oncogene. 2014 Aug 7;33(32):4156-63. doi: 10.1038/onc.2013.397. Epub 2013 Sep 23. PubMed PMID: 24056964; PubMed Central PMCID: PMC3962800.

​

Huang W, Dong Z, Wang F, Peng H, Liu JY, Zhang JT. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion. ACS Chem Biol. 2014 May 16;9(5):1188-96. doi: 10.1021/cb500071v. Epub 2014 Mar 24. PubMed PMID: 24661007; PubMed Central PMCID: PMC4033648.

​

Wu X, Qin L, Fako V, Zhang JT. Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments. Adv Biol Regul. 2014 Jan;54:214-21. doi: 10.1016/j.jbior.2013.09.004. Epub 2013 Sep 15. Review. PubMed PMID: 24080588.

​

Li Z, Peng H, Qin L, Qi J, Zuo X, Liu JY, Zhang JT. Determinants of 14-3-3σ protein dimerization and function in drug and radiation resistance. J Biol Chem. 2013 Nov 1;288(44):31447-57. doi: 10.1074/jbc.M113.467753. Epub 2013 Sep 16. PubMed PMID: 24043626; PubMed Central PMCID: PMC3814741.

​

Liu RY, Dong Z, Liu J, Zhou L, Huang W, Khoo SK, Zhang Z, Petillo D, Teh BT, Qian CN, Zhang JT. Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells. Mol Cancer Ther. 2013 Oct;12(10):2157-66. doi: 10.1158/1535-7163.MCT-12-1190. Epub 2013 Aug 16. PubMed PMID: 23956056; PubMed Central PMCID: PMC3795908.

​

Dong Z, Qi J, Peng H, Liu J, Zhang JT. Spectrin domain of eukaryotic initiation factor 3a is the docking site for formation of the a:b:i:g subcomplex. J Biol Chem. 2013 Sep 27;288(39):27951-9. doi: 10.1074/jbc.M113.483164. Epub 2013 Aug 6. PubMed PMID: 23921387; PubMed Central PMCID: PMC3784709.

​

Yin JY, Dong ZZ, Liu RY, Chen J, Liu ZQ, Zhang JT. Translational regulation of RPA2 via internal ribosomal entry site and by eIF3a. Carcinogenesis. 2013 Jun;34(6):1224-31. doi: 10.1093/carcin/bgt052. Epub 2013 Feb 7. PubMed PMID: 23393223; PubMed Central PMCID: PMC3670257.

​

Liu H, Wu X, Dong Z, Luo Z, Zhao Z, Xu Y, Zhang JT. Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production. J Lipid Res. 2013 Mar;54(3):776-85. doi: 10.1194/jlr.M033811. Epub 2013 Jan 14. PubMed PMID: 23319743; PubMed Central PMCID: PMC3617951.

​